Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 7,942 | 14,980 | 12,496 | 1,729 | 5,097 |
| Gross Profit | 7,942 | 14,980 | 12,496 | 1,729 | 5,097 |
| Operating Expenses | 385,610 | 268,905 | 195,264 | 127,804 | 85,790 |
| Operating Income | -377,667 | -253,925 | -182,768 | -126,075 | -80,693 |
| Interest Expense | 92,346 | 1,368 | 150 | 15,548 | 3,444 |
| Other Income | -8,809 | 10,853 | 28,808 | 1,043 | 8,078 |
| Pre-tax Income | -478,822 | -244,440 | -154,110 | -140,580 | -76,059 |
| Income Tax | -250 | -262 | -465 | -539 | -251 |
| Net Income Continuous | -478,572 | -244,178 | -153,645 | -140,041 | -75,808 |
| Net Income | $-478,572 | $-244,178 | $-153,645 | $-140,041 | $-75,808 |
| EPS Basic Total Ops | -9.46 | -5.25 | -3.74 | -4.16 | -2.86 |
| EPS Basic Continuous Ops | -9.45 | -5.25 | -3.74 | -4.16 | -2.85 |
| EPS Diluted Total Ops | -9.46 | -5.25 | -3.74 | -4.16 | -2.86 |
| EPS Diluted Continuous Ops | -9.45 | -5.25 | -3.74 | -4.16 | -2.85 |
| EPS Diluted Before Non-Recurring Items | -9.46 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-366,875 | $-246,434 | $-181,729 | $-125,245 | $-79,944 |